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A B S T R A C T
The study searched for epidermal growth factor receptor (EGFR) gene amplification in hyperplastic glottis lesions.
After classical pathohistological findings of hematoxylin-eosin (HE) slides and quantitative immunohistochemical (IHC)
analysis, fluorescent in situ hybridization (FISH) was used on tissue microarrays of laryngeal hyperplastic tissue rang-
ing from normal mucosa to abnormal and atypical hyperplastic lesions. FISH analysis of two atypical hyperplastic le-
sions discovered the amplification of EGFR gene while it was not found in simple and abnormal hyperplastic lesions.
The results may indicate that EGFR gene amplifications could possibly correlate with the histopathologic picture. Tissue
samples burdened with specific oncogen signatures like EGFR gene amplification could be detected in precancerous le-
sion. This might improve follow-up and treatment protocols of glottic lesions which are an everyday problem for ENT
practitioners. Further research is mandatory to confirm our findings.
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Introduction
Over-expression of EGFR has been found in precan-
cerous laryngeal lesions and connected with their ad-
vancement and aggressiveness1–3. The relation between
gene amplification and protein over-expression remains
unclear.
Studying EGFR impact on cancerogenesis, scientists
have shown that protein over-expression is not precise
enough for the selection of patients for treatment proto-
cols. Researches indicate that gene alterations can be
useful for the selection of patients suitable for new
anti-EGFR therapies4–8.
There are only a few reports about gene amplification
in laryngeal cancer9–11, and it has not been researched on
hyperplastic glottic tissue. Laryngeal cancer shows a lot
of variability and often multifocal growth also. The biop-
tician must bear this in mind. It is known that different
anatomic locations of laryngeal tumours (glottis, supra-
glottis, subglottis) have different biological behaviour
(metastases, spreading to surrounding tissues). The glot-
tic area is specific since it has the best prognosis. Precan-
cerous lesions of the glottic region with hoarseness as an
early symptom represent one of the major problems of
every day ENT practice. It is important as it is the site of
origin of over 60% of laryngeal cancers and because of its
impact on patients’ quality of life12. This is why we have
investigated EGFR in glottic precancerous lesions.
To evaluate EGFR gene amplification in a large num-
ber of glottic hyperplastic lesions, we have used fluores-
cent in situ hybridisation (FISH) on tissue microarrays,
and have compared the results with classical patho-
histology and immunohistochemistry EGFR protein lev-
els.
Patients and Methods
The research was done on biopsy samples of glottic
hyperplastic tissue harvested from the Department of
Pathology and Otorhinolaryngology of the Rijeka Uni-
versity Hospital Center with the Approval of the Ethics
Committee.
The biopsies were obtained through direct laryngo-
scopy from a vast pool of clinical diagnoses of prolifera-
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tive vocal cord lesions ranging from polyps, oedemas, pa-
pillomas, Singer’s nodules, chronic hypertrophic laryngitis,
leukoplakias and suspected neoplasmas. Slides stained
with hematoxylin-eosin were reviewed by an experienced
pathologist who confirmed the histopathological diagno-
ses.
The hyperplastic lesions were graded according to the
Gale-Kambi~-Lenart Ljubljana classification13 and sub-
sequently divided into groups.
Analysed tissue samples which had simple hyperpla-
sia as the highest mucosal change, were taken as control
samples. Abnormal and atypical hyperplasias were ana-
lysed as precancerous lesions. From a total of 125 HE
slides that entered the study, 41 control samples and 60
precancerous lesions (29 abnormal and 31 atypical hy-
perplasias) were selected by the pathologist for further
IHC and FISH analysis. Seventy-three isolated tissue
specimens of hyperplastic lesions, among which 41 sim-
ple, 15 abnormal, and 17 atypical hyperplasias were ex-
amined. Additionally, for 14 patients with developed la-
ryngeal squamous cell carcinoma (SCC), adjacent areas
of tissue presenting with different grades of hyperplastic
lesions were analysed (14 abnormal and 14 atypical hy-
perplasias).
IHC analysis was successfully performed on all biop-
tic material, while there was some tissue loss during
FISH procedures.
In the control group there were 41% biopsies taken
from male patients and 59% biopsy samples from wo-
men. In precancerous lesions there were only 5.6% fe-
male patients, the rest were male, confirming the fact
that glottic precancerous and cancerous lesions are pre-
dominant in the male population. The range was from 30
to 75 years of age in the control group and from 42 to 79
years of age in patients with precancerous lesions. There
were 75% of smokers in the control group, and 77% of
smokers with precancerous lesions.
Tissue microarray (TMA) construction
Haematoxylin-eosin (HE) stained sections of glottic
mucosa were used to mark areas with surface epithelial
layers, avoiding areas of necrosis. Three tissue cores,
each 1 mm in diameter, were placed in a recipient paraf-
fin block using a manual tissue arrayer (Alphelys, Plaisir,
France). Normal liver tissue was used for slide orienta-
tion. Cores were spaced at intervals of 0.5 mm in the x-
and y-axes. One section from each TMA block was stained
with haematoxylin-eosin for morphological assessment.
Serial sections were cut from TMA blocks for IHC stain-
ing. Five mm thick sections were placed on adhesive glass
slides (Capillary Gap Microscope Slides, 75 mm, Code
S2024, DakoCytomation, Glostrup, Denmark), left to dry
overnight at 37°C and stored in the dark at + 4°C.
Immunohistochemical staining and evaluation of
EGFR expression
Following deparaffinization in xylene and rehydration
in alcohol, heat-induced epitope retrieval was achieved
by immersing the slides in Tris-EDTA buffer (pH 9.0)
and boiling them for 10 minutes in a water bath. Slides
were allowed to cool over 45 minutes, and then pre-incu-
bated for 30 minutes with blocking solution containing
normal donkey (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or goat serum (DakoCytomation, Glostrup,
Denmark), respectively. Sections were incubated with
pre-diluted primary monoclonal antibodies for EGFR
(EGFR pharmDx, Monoclonal Mouse antihuman EGFR
(clone2-18C9)IgG1). Antibody immunohistochemistry was
performed in Dako Autostainer Plus (DakoCytomation
Colorado Inc, Fort Collins, CO, USA) according to the
manufacturer’s protocol, using LSAB technology. All re-
agents for automated IHC were purchased from Dako-
Cytomation (ChemMate TM Detection Kit K5001, Chem-
Mate TM Envision HRP detection Kit K5007). Slides
were counterstained with Mayer’s haematoxylin, dehy-
drated and mounted. Negative control slides were pre-
pared by substituting Dako ChemMate antibody diluent
for a secondary antibody. Moreover, for positive and neg-
ative controls, colonic cancer tissue sections over-ex-
pressing EGFR and apparent normal colonic mucosa
were used.
A quantitative analysis of EGFR expression was per-
formed and membranous staining was evaluated. The
cells were analyzed by layers. The basal zone was defined
as cells with stromal contact; the superficial zone as sur-
face cells with applanated nuclei, and the suprabasal
zone was defined as the transforming layer between
them. The results were analyzed on automated image an-
alyzer using Issa software (VamsTec, Croatia). Statistical
analysis was performed counting all cells on 0.01 mm2 in
defined zones of normal and hyperplastic tissue and cal-
culating the percentages of positive cells.
Fluorescent in situ hybridization
After deparaffinization, the slides were pre-treated
with Paraffin Pretreatment Kit (Vysis, Downers Grove,
IL, USA) using protease to digest proteins for 10 min.
FISH was performed by applying EGFR probe (Vysis,
Downers Grove, IL USA): LSI EGFR SpectrumOrange
and CEP 7 SpectrumGreen for respective centromeric
region at chromosome 7. The LSI EGFR Dual Color
probe hybridizes to the band region 7p12 in Spectrum
Orange and the CEP 7 to the 7p11.1-q11, 1, D7Z1 locus
in Spectrum Green. Denaturation of the probe mixture
was performed at 95 °C for 5 min. in Thermobrite
(Abbott Molecular Inc, IL, USA) followed by overnight
hybridization at 37 °C. The following day, cover glass was
removed and slides were washed in post-hybridization
washing-buffer (Vysis, Downers Grove, IL, USA) at 72 °C
for 2 minutes. After drying, DAPI (Vysis, Downers Grove,
IL, USA) was applied and slides were protected from
light at –20 °C until reading. Automated scanning, cap-
ture and scoring of interphase FISH was analyzed by
Cytovision System (Applied Imaging Corp., San Jose,
USA). EGFR gene amplification was defined as a ratio
between EGFR gene (orange) and centromere (green)
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signals in cell nuclei over 2.2, or the presence of EGFR
gene clusters.
Statistical analysis
Statistical analysis between the three groups was car-
ried out using Kruskal-Wallis test. For differences be-
tween single group pairs, the Mann-Whitney test was ap-
plied. The level of statistical significance was set at
P<0.050. For statistical analysis, SPSS 15.0 software
was used.
Results
IHC analysis was successfully performed on 41 sim-
ple, 29 abnormal and 31 atypical hyperplasias chosen by
an experienced pathologist.
To evaluate membranous EGFR (mEGFR) protein
over-expression through epithelial layers, we calculated
the percentages of positive cells in the basal and supra-
basal layers (2/3 of the epithelium) and all the layers (en-
tire epithelial thickness), based on previous research1–3
(Figure 1).
The percentage of positive cells in the basal and
suprabasal layer (2/3 of the epithelium) and all the layers
(entire epithelial thickness) was statistically higher in
atypical than in abnormal hyperplastic lesions (P<0.050,
Mann-Whitney test). Abnormal and atypical hyperplas-
ias had statistically higher percentages of mEGFR posi-
tive cells in the basal and suprabasal layers as well as in
the entire epithelial thickness than simple hyperplasias
taken as control samples (P<0.05, Kruskal-Wallis test,
Figure 1).
Membranous EGFR protein expression gradually in-
creased from negative to weak positive and strong positive
throughout all layers with increased atypia, indicating
that mEGFR staining can facilitate the differentiation
between different degrees of atypia among hyperplastic
lesions.
No statistical difference of mEGFR protein expres-
sion was found between isolated hyperplastic lesions and
specimens with the same degree of atypia adjacent to tu-
mour samples.
Epidermal growth factor receptor gene in situ
hybridization (FISH)
FISH was successful for 37 simple, 23 abnormal and
26 atypical hyperplastic glottic tissue samples. There was
some loss of tissue material during TMA sectioning and
hybridization procedures.
Amplification was detected in 2 tissue samples that
showed 5 or more signals or clusters of EGFR gene.
There was no amplification in the control group and
abnormal hyperplastic lesions (Figure 2a). Both amplifi-
cations were found in atypical hyperplasias (Figure 2b).
One entered the study under the clinical diagnosis of sus-
pected neoplasma of the vocal cord. The other was found
on atypical hyperplasia adjacent to SCC.
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Fig. 1. Percentages of membranous positive cells for epidermal
growth factor receptor (EGFR) in simple, abnormal and atypical
hyperplastic lesions.
Fig. 2. Fluorescent in situ hybridization (FISH) for epidermal
growth factor receptor (EGFR) gene in glottic lesions. DNA probes:
Spectrum Orange-labeled for EGFR gene, and Spectrum Green-
-labeled centromeric probe for chromosome 7. a) Control sample:
no EGFR gene amplification (magnification 100x). b) EGFR gene
amplification in atypical hyperplasia: the score between EGFR
gene (orange) and centromere (green) signals in cell nuclei over
2.2 (magnification 100x).
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There was no statistical significance between mEGFR
protein expression of amplified atypical lesions and those
without EGFR gene amplification.
Discussion
In this study, we used tissue microarray technology
(TMA) on samples of laryngeal mucosa ranging from
simple, abnormal to atypical hyperplastic lesions.
Using FISH, it was possible to detect gene amplifica-
tion in glottic lesions and compare results with standard
pathohistology and IHC protein levels of EGFR.
Based on pathohistologycal findings, the distinction
was made between abnormal and atypical hyperplasias
because of their different biological behaviour. Abnormal
hyperplasias can be regenerative, while atypical lesions
have a more malignant potential and require different
treatment. Hyperplastic lesions of the glottic region cover
a wide spectrum of histomorphologic changes. In every-
day practice, histopathology results based on traditional
light microscopy represent the basis of diagnosis. For di-
agnostically difficult cases, nowadays pathohistology is
not precise enough in protocol decisions, and IHC analy-
sis is used in many clinical centres.
EGFR protein expression usually increases with de-
grees of atypia1–3,14,15, as it was in this study. Our re-
search did not find statistical differences in mEGFR pro-
tein levels of isolated laryngeal lesions with the same
lesions adjacent to SCC as some authors’ did3. The evalu-
ation of EGFR protein over-expression can sometimes be
difficult in a multilayered epithelium, and high levels of
EGFR protein can often be found even in simple and ab-
normal hyperplastic lesions1,3,14. This research also de-
tected high levels of EGFR protein in some control sam-
ples and abnormal hyperplastic lesions, but none of them
showed gene amplification which seems to lead to the
transformation of atypical lesions into cancerous tissue.
It was detected in 2 highly atypical lesions. One of them
developed into preinvasive cancer within one month of
follow-up. The other was found in atypical hyperplasia
adjacent to SCC. Although two cases of amplifications
are a humble number, the fact that none of them was
found in simple or abnormal hyperplastic lesions but
only in the group of atypical lesions (that developed into
or were found next to cancerous tissue) may indicate that
amplifications could possibly correlate with the histopa-
thological picture, making identification of biologically
more aggressive lesions easier.
Detection of EGFR gene amplification might help the
distinction of lesions that carry a higher risk of progres-
sion into cancerous tissue. This genetically changed and
instable tissue could be diagnosed before its passage from
malignant genotype into phenotype and help prevent
cancer formation. Hypothesis of cancer development in
the head and neck region have been discussed as early as
the 1990. The field cancerisation concept suggests car-
cinogen exposed tissue accumulates genetic changes pro-
gressing from dysplasia (atypical hyperplasia) into can-
cerous tissue16. The second hypothesis presumes that
head and neck cancer arise frommicrometastatic foci of a
single progenitor clone17. Research of a specific area such
as the glottic region is lacking. Laryngeal cancer often
shows multifocal growth. This must be taken into ac-
count when biopsies are taken. Often the pathologist can
find different types of hyperplasias adjacent to cancerous
tissue on the same slide. Cases of repeated relapses of
atypical hyperplasias still divide clinicians on follow-up
and treatment protocols. Perhaps the site of biopsy pres-
ents the hystologic picture of atypical hyperplasia but ad-
jacent tissue that was not included in the specimen al-
ready holds the features of preinvasive tumour, and even
though multiple and repeated biopsies are taken as a rule
by most practitioners, mistakes in grading the aggres-
siveness of a lesion cannot be avoided in some cases. Re-
searchers have previously investigated genetic instabili-
ties in glottic lesions and chromosome 7 aberrations have
been found in dysplastic and cancerous laryngeal tissue
and connected with prognosis3, 18,19, but gene analysis is
insufficient. This is why we have investigated EGFR
gene amplification in glottic lesions and EGFR gene am-
plification in atypical hyperplasias is an entirely new
finding. Further research, which is currently being un-
dertaken at our Clinic, is mandatory to confirm the sig-
nificance of our findings.
Glottic precancerous lesions are important because of
their high incidence and influence on quality of life. Se-
lection of patients with atypical lesions that hold a more
malignant potential would greatly help better follow-up
and treatment of these lesions that represent a major
problem in everyday ENT practice. In these lesions bio-
markers like EGFR could help in decision making. Early
glottic cancer (Tis-T1T2N0M0) is an entity that can be
treated by radiotherapy or surgery. Literature data indi-
cate that EGFR can help in the selection of patients suit-
able for radiotherapy20,21,22. The significance of EGFR
gene amplification on laryngeal radiosensitivity has not
been researched yet. Also, a new area of interest cur-
rently under investigation at our Clinic is nuclear EGFR
protein expression, the role of which, according to pub-
lished data, still remains unclear23,24,25. Our final purpose
is to determine subpopulations of lesions with different
EGFR status in order to optimize their treatment ac-
cordingly. This might be helpful for decision making in
precancerous lesions, as well as defining therapeutic pro-
tocols for laryngeal cancer (radioresistance, involvement
in monoclonal antibody treatments with regard to EGFR
status).
The importance of glottic lesions for patient’s quality
of life raises the need for individualized therapies and op-
timal treatment protocols based upon molecular mark-
ers. We hope that our research can add to higher aware-
ness of EGFR in glottic hyperplastic lesions. Still many
open questions and insufficient data indicate the need
for further research in this field.
Conclusion
For optimal treatment and follow-up of precancerous
glottic tissue lesions, subpopulations of patients with
specific molecular signatures are needed.
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The study discovered two cases of EGFR gene amplifi-
cation in atypical hyperplastic lesions. No EGFR gene am-
plification was found in simple or abnormal hyperplasias.
Since IHC analysis of glottic hyperplasias sometimes
lacks precision, our research indicates that in diagnosti-
cally difficult cases detection of EGFR gene amplification
might point to the aggressive nature of the lesion, im-
proving the accuracy of diagnosis and therapy choices of
glottic lesions. Further research is needed to confirm the
significance of our findings in glottic precancerous le-
sions
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GENSKA AMPLIFIKACIJA RECEPTORA EPIDERMALNOG FAKTORA RASTA U ATIPI^NIM
HIPERPLAZIJAMA GLOTISA
S A @ E T A K
Studija istra`uje gensku amplifikaciju receptora epidermalnog faktora rasta (EGFR) u atipi~nim hiperplazijama
glotisa. Nakon klasi~ne patohistolo{ke i imunohistokemijske (IH) analize, kori{tena je fluorescentna in situ hibridiza-
cija (FISH) na tkivnim mikroarejima hiperplasti~nih gloti~nih uzoraka razli~itog stupnja atipije. Genska amplifikacija
nije na|ena u jednostavnim i abnormalnim hiperplazijama.Otkrivena je u dvije visoko rizi~ne atipi~ne hiperlpasti~ne
lezije.Tkivni uzorci optere}eni odre|enim onkogenim promjenama poput EGFR genske amplifikacije mogli bi biti otkri-
veni u prekanceroznim lezijama, sprije~iv{i njihovu malignu transformaciju. Navedeno bi moglo pobolj{ati protokole
pra}enja i lije~enja gloti~nih prekanceroznih lezija koje predstavljaju veliki problem svakodnevne ORL prakse. Daljnja
su istra`ivanja potrebna da potvrde na{e rezultate.
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